White House Withdraws FDA Nominee Overton as Senate Health Committee Scraps Vote

3 min read
Source: Talking Points Memo
White House Withdraws FDA Nominee Overton as Senate Health Committee Scraps Vote
Photo: Talking Points Memo
TL;DR

The White House withdrew its nomination for Dr. Heidi Overton to lead the Food and Drug Administration on Tuesday night, hours before a scheduled Senate vote. Overton faced opposition from both anti-abortion activists and moderate Republicans, creating an unresolvable conflict for the administration. The withdrawal leaves the FDA without a permanent commissioner, a vacancy that has persisted since May. The Senate Health, Education, Labor, and Pensions (HELP) committee subsequently canceled a vote on another nominee, Jim O’Neill, for the National Science Foundation. The administration is now considering Senator Roger Marshall as a replacement, though he faces his own conflicts with the Make America Healthy Again (MAHA) movement.

Key points

  • The White House withdrew Dr. Heidi Overton’s nomination for FDA commissioner on Tuesday night, citing a lack of support in Congress.
  • Overton’s confirmation was blocked by a split between anti-abortion groups demanding stricter mifepristone rules and moderate Republicans opposing her anti-vaccine stances.
  • The FDA has lacked a permanent commissioner since Marty Makary resigned in May, currently operating under acting leadership.
  • The Senate HELP committee canceled a vote on Jim O’Neill, the nominee for the National Science Foundation, following the Overton withdrawal.
  • Senator Roger Marshall is being considered as a potential replacement, though he opposes glyphosate bans, a key MAHA litmus test.

Background

The FDA has been without a permanent leader since Marty Makary resigned in May 2026 after clashing with the White House over vape authorizations and mifepristone restrictions. The agency is currently led by acting commissioner Kyle Diamantas, who is reportedly planning to leave the post. This instability occurs amid broader tensions within the administration, including the recent resignation of Chief of Staff Susie Wiles and a shift toward hardliner Stephen Miller following the 2026 midterm elections.

How outlets are covering it

The New York Times and Ars Technica report that Overton lacked the necessary votes to advance, with the latter noting she stonewalled senators during her hearing. TPM emphasizes the structural conflict between the MAGA and MAHA movements, noting that anti-abortion advocates were incensed by the administration’s failure to restrict mifepristone, while moderate Republicans like Susan Collins and Lisa Murkowski opposed Overton’s anti-vaccine positions. Semafor highlights the time crunch, noting that Republicans have only six weeks left in their majority to confirm nominees. Ars Technica also reports that the HELP committee canceled a vote on Jim O’Neill, the NSF nominee, citing his lack of science experience and his role in firing CDC director Susan Monarez.

Why it matters

The withdrawal of Overton highlights the deep internal fractures within the Trump administration’s health policy agenda. The inability to confirm a FDA commissioner leaves critical regulatory decisions, including the safety review of mifepristone and the deregulation of peptides, in limbo. This vacuum may allow the administration to delay controversial actions or force through policies via acting officials, potentially undermining the scientific integrity of the agency and exacerbating political polarization over public health issues.

What to watch

The White House is expected to announce a new nominee for the FDA, with Senator Roger Marshall being a primary candidate. The administration must navigate the remaining six weeks of Republican control in the Senate to confirm any new appointees before the 120th Congress ends. The HELP committee may also revisit the nomination of Jim O’Neill for the National Science Foundation, though his prospects remain uncertain given the concerns raised by committee members.

Share this article

Want the full story? Read the original reporting

Read on Talking Points Memo